Enzyme Aptamer Screening Service is a specialized contract research service where providers employ SELEX (Systematic Evolution of Ligands by EXponential Enrichment) to discover aptamers that bind with high specificity and affinity to a target enzyme. These aptamers can be designed not only to bind but also to modulate the enzyme's activity (inhibit or activate), making them powerful tools for therapeutics, diagnostics, and biochemical research. Key Differentiators from Antibody Screening: Functional Screening: A major goal is often to identify inhibitory or activating aptamers. Therefore, the screening process may incorporate activity-based selection or functional assays early on. Target Site Complexity: The target can be the entire enzyme, its active site, an allosteric site, or a specific conformational state (e.g., open vs. closed). Conformational Sensitivity: Enzymes are dynamic. Aptamers can be selected to recognize a specific functional conformation, which is a unique advantage. Typical Screening Workflow: 1. Project Design & Target Preparation: Define Objective: Is the goal pure detection, potent inhibition, allosteric modulation, or capturing a specific enzyme form? Enzyme Quality: Requires a highly pure, functional, and correctly folded enzyme. Activity assays confirm functionality. Selection Strategy: Choice of Toggle SELEX (for broad species cross-reactivity), Capture SELEX, or innovative methods like ExSELEX (for complex biological fluids). 2. The SELEX Process with a Functional Focus: Binding & Stringency: Standard incubation, washing, and elution cycles are performed. Functional Partitioning (Optional…
What is an Antibody Aptamer Screening Service? It is a specialized contract research service where a biotechnology company uses SELEX (Systematic Evolution of Ligands by EXponential Enrichment) or advanced variations of it to discover and develop aptamers that bind with high affinity and specificity to a target antibody. Antibody: A large, Y-shaped protein produced by the immune system to identify and neutralize pathogens. Aptamer: A short, single-stranded DNA or RNA oligonucleotide (or a modified derivative) that folds into a specific 3D structure, enabling it to bind to a target molecule with antibody-like specificity. Often called "chemical antibodies." The goal of the service is to provide clients with synthetic, recombinant-like binding molecules as alternatives or complements to traditional monoclonal antibodies. Why Screen for Aptamers Against Antibodies? Aptamers offer distinct advantages, making them attractive for various applications: Anti-Drug Antibody (ADA) Detection: Develop aptamer-based assays to detect and quantify ADAs in clinical trials for biotherapeutics. Diagnostic Tools: Create aptamer sensors (aptasensors) to detect specific antibody biomarkers for diseases (e.g., autoantibodies in autoimmune disorders). Therapeutic Neutralization: Discover aptamers that can bind and neutralize pathological antibodies (e.g., in autoimmune diseases like lupus or myasthenia gravis). Purification & Pull-Down: Use aptamers as ligands in chromatography or in assays to capture and isolate specific antibodies from complex…
What is an Aptamer? First, a quick definition: Aptamers are short, single-stranded DNA or RNA oligonucleotides that bind to a specific target molecule (like proteins, toxins, cells) with high affinity and specificity. They are often called "chemical antibodies" but offer advantages like easier synthesis, higher stability, and lower cost. What is Toxin-Targeted Aptamer Screening? This service involves the in vitro selection and development of custom aptamers designed to bind specifically to a toxic substance. The core technology is called SELEX (Systematic Evolution of Ligands by EXponential enrichment). The process screens vast random libraries (10^14 - 10^15 different sequences) against the toxin to isolate the few sequences that bind tightly and specifically. Key Steps in the Service Pipeline Project Consultation & Target Definition: Clarify the toxin (e.g., mycotoxins like Aflatoxin B1, marine toxins like Saxitoxin, bacterial toxins like Botulinum, environmental toxins like heavy metals). Define the desired application (Detection/Biosensing, Neutralization, Capture/Purification). Specify the sample matrix (food extract, blood serum, environmental water). Library Design & SELEX Strategy: Design of a naive single-stranded DNA or RNA library. Choosing the appropriate SELEX variant: Negative Selection/Counter-SELEX: To exclude sequences that bind to similar non-toxin molecules or the assay matrix (crucial for specificity). Capture-SELEX: For small toxins that can't be immobilized. Cell-SELEX: If the…
Core Technology: SELEX The foundation of all these services is the SELEX process, an in vitro method to select aptamers from a vast random library (typically 10^13 - 10^15 unique sequences). The library is incubated with the target, unbound sequences are washed away, and bound sequences are eluted and amplified by PCR (for DNA) or RT-PCR (for RNA). This cycle is repeated 8-15 times to enrich for the tightest binders. Services for Protein Targets This is the most common application, as aptamers are often touted as "chemical antibodies." 1. Standard Protein SELEX: Target: Purified, recombinant proteins (e.g., cytokines, receptors, enzymes, viral capsids). Key Considerations: Protein Purity & Conformation: Critical for success. Services often require >90% purity and verification of native folding. Immobilization: The protein is usually immobilized on beads (e.g., streptavidin/biotin, Ni-NTA/His-tag) to facilitate partitioning. Some services offer solution-phase SELEX to avoid conformation changes. Counter-Selection: To ensure specificity, libraries are pre-incubated with related proteins or the immobilization matrix to subtract non-specific binders. 2. Specialized SELEX for Complex Proteins: Membrane Protein SELEX: For receptors and channels. Requires special handling (e.g., use of nanodiscs, detergent micelles, or whole cells overexpressing the target). Post-Translationally Modified Protein SELEX: For targets where phosphorylation, glycosylation, etc., are essential for function. 3. Cell-SELEX (for Cell-Surface…
What is an Aptamer Screening Service? It is a contract-based service where a specialized laboratory uses Systematic Evolution of Ligands by EXponential enrichment (SELEX) to discover single-stranded DNA or RNA molecules (aptamers) that bind with high affinity and specificity to your target molecule (e.g., a protein, an antibody's constant region, or a cell-surface receptor). Core Service Components A full-service provider typically offers an end-to-end pipeline: 1. Project Design & Target Preparation Consultation: Defining the goal (e.g., detection, inhibition, delivery). Target Characterization: Ensuring the target (purified protein, antibody, receptor-expressing cells) is properly formatted and validated. Negative Selection/Counter-SELEX: Designing the screening to avoid binders to similar, non-target structures (e.g., the Fc region of a different antibody isotype, a common cell surface protein). 2. Library & Selection (The Core SELEX Process) Library Design: Using a diverse random oligonucleotide library (typically 10^14 - 10^15 unique sequences). Selection Method: The choice of method is critical and depends on the target: Protein SELEX: For purified, soluble targets immobilized on beads or in solution. Cell-SELEX: For membrane receptors in their native conformation on live cells. Excellent for discovering aptamers to unknown receptor complexes. Capture-SELEX/Toggle-SELEX: For difficult-to-immobilize targets or to increase stringency. In Vivo SELEX: For discovering aptamers that home to specific tissues in vivo. Iterative Rounds: Typically 8-15 rounds of…
What is an Aptamer? An aptamer is a short, single-stranded DNA or RNA oligonucleotide that folds into a specific 3D structure, allowing it to bind to a target molecule (like a cytokine) with high affinity and specificity, akin to a monoclonal antibody. Why Target Cytokines with Aptamers? Cytokines are key signaling proteins in immune and inflammatory responses. Dysregulation is implicated in diseases like: Autoimmune disorders: Rheumatoid arthritis, psoriasis, inflammatory bowel disease. Cancer: Tumor microenvironment signaling. Cytokine Storms: Severe COVID-19, sepsis. Neurological diseases. Aptamers offer advantages over traditional antibody-based therapies: High Specificity: Can distinguish between closely related cytokine isoforms or conformational states. Controlled Synthesis: Chemically produced, no batch-to-batch variation. Modifiability: Easily conjugated with drugs, fluorophores, or nanoparticles. Low Immunogenicity: Less likely to cause an immune response. Stability: Generally more stable than proteins. The Aptamer Screening Service Workflow (SELEX) A professional service will manage the entire SELEX (Systematic Evolution of Ligands by EXponential Enrichment) process. Here’s a typical pipeline: Phase 1: Project Design & Target Preparation Consultation: Define the goal—neutralization, detection, or delivery. Target Selection: Which cytokine? (e.g., TNF-α, IL-6, IL-1β, IFN-γ). Requires a high-purity, bioactive protein. Services often help with recombinant expression/purification if needed. Library Design: A vast random-sequence oligonucleotide library (10^14-10^15 unique sequences) is the starting point. Libraries can be DNA, RNA, or contain modified…
Why Target Protein Kinases with Aptamers? Protein kinases are a large family of enzymes that regulate almost all cellular processes by phosphorylating target proteins. Their dysregulation is a hallmark of many diseases, especially cancer, making them prime therapeutic targets. Advantages of Aptamers over Traditional Kinase Inhibitors: High Specificity: Can be selected to distinguish between highly conserved kinase family members or even between active/inactive conformations. Modifiable Chemistry: Easy chemical modification for stability (e.g., 2'-F, 2'-O-methyl) and labeling (e.g., fluorophores, biotin). Non-Immunogenic: Unlike antibodies, they are chemically synthesized, reducing batch-to-batch variability. Reversible Inhibition: Typically act as competitive inhibitors, which can be desirable for certain therapeutic strategies. Cell-Permeable Versions: Spiegelmers (L-aptamers) or nanoparticle conjugation can enable intracellular targeting. Core Screening Service Workflow (SELEX) The service revolves around SELEX (Systematic Evolution of Ligands by EXponential Enrichment), specifically optimized for kinases. 1. Project Design & Library Selection: Target Definition: Which kinase? Which conformation (active, inactive, substrate-bound)? Which domain (catalytic, regulatory)? Library Design: Standard DNA/RNA libraries or modified (e.g., 2'-F pyrimidines for nuclease resistance). Library diversity is typically >10^14 unique sequences. 2. Target Preparation: Protein Quality is Critical: The kinase must be highly pure, correctly folded, and functional. Services often use recombinant kinases with tags (GST, His) for immobilization. Immobilization Strategy: Crucial step. Common methods include: Biotin-Streptavidin: Biotinylated…
What is an Aptamer? An aptamer is a short, single-stranded DNA or RNA oligonucleotide that binds to a specific target molecule (like a protein) with high affinity and specificity. They are often called "chemical antibodies" but offer advantages like smaller size, chemical stability, and in-vitro generation. The Core Service: SELEX (Systematic Evolution of Ligands by EXponential Enrichment) The standard method for aptamer screening is SELEX. A specialized service will manage this entire iterative, high-complexity process for you. General SELEX Workflow: Target Preparation & Immobilization: Your service provider will prepare your purified protein. It is often immobilized on a solid support (beads, column, plate) to separate bound from unbound sequences. Incubation with Library: A vast, random synthetic oligonucleotide library (10^13 - 10^15 unique sequences) is incubated with the target. Partitioning: Weak or non-binding sequences are washed away. Tightly bound aptamers are retained. Elution & Amplification: The bound sequences are eluted and amplified by PCR (for DNA) or RT-PCR (for RNA). Stringency & Counter-SELEX: Subsequent rounds introduce increased washing stringency and incubation with non-target molecules (e.g., similar proteins, immobilization matrix) to filter out non-specific binders. This is crucial for specificity. Cloning & Sequencing: After 8-15 rounds, the enriched pool is cloned and sequenced to identify individual candidate aptamers. Characterization &…
Aptamer Screening via HT-SELEX (High-Throughput Systematic Evolution of Ligands by Exponential Enrichment) is the modern, powerful method for discovering aptamers. Let's break down what this service entails, its process, advantages, and key considerations. What is an Aptamer? First, a quick reminder: Aptamers are single-stranded DNA or RNA oligonucleotides that bind to a specific target molecule (proteins, small molecules, cells, viruses) with high affinity and specificity, analogous to antibodies. They are often called "chemical antibodies." What is HT-SELEX? Traditional SELEX is iterative and low-throughput. HT-SELEX supercharges this process by integrating: Next-Generation Sequencing (NGS): To analyze the entire aptamer pool at each round. Advanced Bioinformatics: To identify binding motifs and track enrichment. Automation: Using robotics for partitioning (e.g., magnetic beads, microfluidics) to increase throughput and reproducibility. This results in a faster, more efficient, and data-driven screening process. Standard HT-SELEX Service Workflow A typical service provider will follow these steps: 1. Project Design & Library Synthesis Target Preparation: You provide the target (recombinant protein, small molecule conjugate, whole cell, etc.). Its purity and stability are critical. Library Design: A randomized oligonucleotide library is synthesized (typically 10^14 - 10^15 unique sequences). Libraries can be DNA, RNA, or modified nucleotides (e.g., SOMAmers) for enhanced stability and affinity. 2. The Selection Rounds (Cycles of…
Core Concept of NGS-SELEX Traditional SELEX uses a few rounds of selection and cloning/Sanger sequencing of a handful of clones. NGS-SELEX performs deep sequencing (millions to billions of reads) at every selection round. This allows you to: Track the entire evolution of the oligonucleotide pool in real-time. Identify enriched sequences and families early. Perform sophisticated bioinformatics analysis to find winners, not just rely on final round abundance. Dramatically reduce the number of selection rounds needed (often 3-6 rounds instead of 8-15). Standard Service Workflow A full-service provider would typically offer the following pipeline: 1. Project Design & Library Synthesis Consultation: Target properties (protein, small molecule, cell), desired aptamer properties (Kd, specificity, buffer conditions). Library Design: Standard (40-60 nt random region) or custom (doped libraries, modified nucleotides like 2'-F, 2'-OMe, SOMAmers). Primer & Library Synthesis: Providing the initial, highly diverse DNA or RNA library (10^14 - 10^15 unique sequences). 2. SELEX Selection Immobilization: Immobilizing the target (on beads, column, plate) or using solution-based techniques (capture-SELEX, toggle-SELEX). Counter-Selection: Including steps to remove binders to immobilization matrix or off-targets. Stringency Control: Increasing selection pressure over rounds (e.g., reduced target concentration, increased wash stringency). Amplification: Careful PCR (with optimization to minimize bias) to regenerate the pool for the next round. 3. NGS & Core Bioinformatics Sample Preparation: Preparing sequencing…
